Clinical effectiveness and adverse events associated with tolvaptan in patients above 90 years of age with acute decompensated heart failure
- 2 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Heart and Vessels
- Vol. 36 (6), 836-843
- https://doi.org/10.1007/s00380-020-01753-3
Abstract
With the aging society, the number of very-elderly (VE) patients with acute decompensated heart failure (ADHF) is increasing. Although tolvaptan is recommended for patients with ADHF in whom conventional diuretic therapy is ineffective, few reports exist on VE patients over 90 years of age. Therefore, we aimed to evaluate the clinical effectiveness and adverse events associated with tolvaptan in VE patients with ADHF. From January 2011 to December 2018, we retrospectively studied 180 patients with ADHF who were first administered tolvaptan during hospitalization. Patients were divided into two groups, namely, VE patients who were ≥ 90 years of age (n = 32) and not-VE patients (NVE) who were < 90 years of age (n = 148). The primary effective endpoints were the total urine volume and change in body weight. The safety endpoints evaluated were the incidence of hypernatremia (≥ 150 mEq/L) and worsening renal function (WRF) at any time during hospitalization. The median [interquartile range] patient age was 93 [91–94] years in the VE group and 80 [69–85] years in the NVE group. The mean dose of tolvaptan for the first week of administration was similar between groups (7.9 ± 5.0 mg, VE group; 7.3 ± 3.7 mg, NVE group; p = 0.52). There were no significant differences between the two groups in the total urine volume at 24 h (1901 ± 666 mL, VE group; 2101 ± 1167 mL, NVE group; p = 0.33) and that at 48 h (3707 ± 1274 mL, VE group; 4195 ± 1990 mL, NVE group; p = 0.19) and in the mean change in body weight (− 2.5 ± 2.0 kg, VE group; -2.7 ± 2.4 kg, NVE group; p = 0.70). The median duration of hospitalization was 24 [20–9] and 31 [20–42] days in the VE and NVE groups, respectively (p = 0.67). The incidence of hypernatremia (6.3% (2/32), VE group; 3.4% (5/148), NVE group; p = 0.61) and WRF (25.0% (8/32) VE group; 19.6% (29/148), NVE group; p = 0.31) was similar between the groups. In conclusion, tolvaptan has similar clinical effectiveness in increasing urine volume and decreasing body weight, without increased adverse events, in VE patients with ADHF who were ≥ 90 years of age compared to NVE patients with ADHF.Keywords
Funding Information
- Otsuka Pharmaceutical
This publication has 26 references indexed in Scilit:
- Clinical Effectiveness of Tolvaptan in Patients with Acute Decompensated Heart Failure and Renal Failure: Design and Rationale of the AQUAMARINE StudyCardiovascular Drugs and Therapy, 2013
- Differential clinical characteristics and outcome predictors of acute heart failure in elderly patientsInternational Journal of Cardiology, 2012
- Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalizationAmerican Heart Journal, 2010
- Association between hypernatraemia acquired in the ICU and mortality: a cohort studyNephrology Dialysis Transplantation, 2010
- Incidence and prognosis of dysnatremias present on ICU admissionIntensive Care Medicine, 2009
- Transient worsening of renal function during hospitalization for acute heart failure alters outcomeInternational Journal of Cardiology, 2008
- Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart FailureThe EVEREST Clinical Status TrialsJAMA, 2007
- Acute Vasoconstrictor Response to Intravenous Furosemide in Patients with Chronic Congestive Heart FailureAnnals of Internal Medicine, 1985
- The Natural History of Congestive Heart Failure: The Framingham StudyThe New England Journal of Medicine, 1971
- Diuretic Action of FurosemideArchives of Internal Medicine, 1965